S&P 500   5,099.59 (+0.59%)
DOW   39,008.64 (+0.15%)
QQQ   438.97 (+0.85%)
AAPL   180.15 (-0.70%)
MSFT   410.83 (+0.76%)
META   488.84 (+1.00%)
GOOGL   137.46 (+0.79%)
AMZN   175.20 (+1.18%)
TSLA   200.97 (-0.53%)
NVDA   797.17 (+2.64%)
NIO   5.66 (+4.24%)
AMD   192.48 (+9.03%)
BABA   73.90 (-0.93%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   90.01 (+0.33%)
CGC   3.29 (-2.08%)
GE   156.84 (+0.79%)
DIS   111.62 (+0.74%)
AMC   4.32 (-13.43%)
PFE   26.72 (-1.18%)
PYPL   60.17 (-0.13%)
XOM   104.80 (+0.46%)
S&P 500   5,099.59 (+0.59%)
DOW   39,008.64 (+0.15%)
QQQ   438.97 (+0.85%)
AAPL   180.15 (-0.70%)
MSFT   410.83 (+0.76%)
META   488.84 (+1.00%)
GOOGL   137.46 (+0.79%)
AMZN   175.20 (+1.18%)
TSLA   200.97 (-0.53%)
NVDA   797.17 (+2.64%)
NIO   5.66 (+4.24%)
AMD   192.48 (+9.03%)
BABA   73.90 (-0.93%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   90.01 (+0.33%)
CGC   3.29 (-2.08%)
GE   156.84 (+0.79%)
DIS   111.62 (+0.74%)
AMC   4.32 (-13.43%)
PFE   26.72 (-1.18%)
PYPL   60.17 (-0.13%)
XOM   104.80 (+0.46%)
S&P 500   5,099.59 (+0.59%)
DOW   39,008.64 (+0.15%)
QQQ   438.97 (+0.85%)
AAPL   180.15 (-0.70%)
MSFT   410.83 (+0.76%)
META   488.84 (+1.00%)
GOOGL   137.46 (+0.79%)
AMZN   175.20 (+1.18%)
TSLA   200.97 (-0.53%)
NVDA   797.17 (+2.64%)
NIO   5.66 (+4.24%)
AMD   192.48 (+9.03%)
BABA   73.90 (-0.93%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   90.01 (+0.33%)
CGC   3.29 (-2.08%)
GE   156.84 (+0.79%)
DIS   111.62 (+0.74%)
AMC   4.32 (-13.43%)
PFE   26.72 (-1.18%)
PYPL   60.17 (-0.13%)
XOM   104.80 (+0.46%)
S&P 500   5,099.59 (+0.59%)
DOW   39,008.64 (+0.15%)
QQQ   438.97 (+0.85%)
AAPL   180.15 (-0.70%)
MSFT   410.83 (+0.76%)
META   488.84 (+1.00%)
GOOGL   137.46 (+0.79%)
AMZN   175.20 (+1.18%)
TSLA   200.97 (-0.53%)
NVDA   797.17 (+2.64%)
NIO   5.66 (+4.24%)
AMD   192.48 (+9.03%)
BABA   73.90 (-0.93%)
T   17.00 (+0.24%)
F   12.40 (+0.81%)
MU   90.01 (+0.33%)
CGC   3.29 (-2.08%)
GE   156.84 (+0.79%)
DIS   111.62 (+0.74%)
AMC   4.32 (-13.43%)
PFE   26.72 (-1.18%)
PYPL   60.17 (-0.13%)
XOM   104.80 (+0.46%)

Indivior (INDV) Stock Forecast & Price Target

$21.45
-0.45 (-2.05%)
(As of 03:45 PM ET)

Indivior Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

$35.00
63.17% Upside
High Forecast$35.00
Average Forecast$35.00
Low Forecast$35.00
TypeCurrent Forecast
3/1/23 to 2/29/24
1 Month Ago
1/30/23 to 1/30/24
3 Months Ago
12/1/22 to 12/1/23
1 Year Ago
3/1/22 to 3/1/23
Consensus Rating
Buy
Buy
Buy
N/A
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
N/A
Buy
1 Buy rating(s)
1 Buy rating(s)
1 Buy rating(s)
N/A
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
N/A
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
N/A
Consensus Price Target$35.00$35.00$35.00N/A
Predicted Upside63.17% UpsideN/AN/AN/A
Get Indivior Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.


INDV Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INDV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Indivior Stock vs. The Competition

TypeIndiviorMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.48
Consensus RatingBuyModerate BuyHold
Predicted Upside59.82% Upside1,853.88% Upside7.87% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/13/2023Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$35.00+350,000,000.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:06 PM ET.












INDV Price Target - Frequently Asked Questions

What is Indivior's consensus rating and price target?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Indivior stock is Buy based on the current 1 buy rating for INDV. The average twelve-month price prediction for Indivior is $35.00 with a high price target of $35.00 and a low price target of $35.00. Learn more on INDV's analyst rating history.

Do Wall Street analysts like Indivior more than its competitors?

Analysts like Indivior more than other Medical companies. The consensus rating for Indivior is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how INDV compares to other companies.


Stock Ratings Reports and Tools

This page (NASDAQ:INDV) was last updated on 2/29/2024 by MarketBeat.com Staff